New drug combo shows promise for Hard-to-Treat blood cancers
NCT ID NCT04588922
First seen Mar 18, 2026 · Last updated Apr 24, 2026 · Updated 8 times
Summary
This study tests a new drug called SLS009 (formerly GFH009) in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. The drug is given alone or with other cancer medicines (venetoclax and azacitidine). The goal is to see if it is safe and can shrink or control the cancer. About 160 adults and some teens will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Chongqing University
WITHDRAWNChongqing, Chongqing Municipality, China
-
Affiliated Hospital of Hebei University
COMPLETEDBaoding, Hebei, China
-
Anhui Provincial Hospital
COMPLETEDHefei, Anhui, China
-
Baylor Scott & White Health
RECRUITINGDallas, Texas, 75246, United States
Contact
-
Blood disease hospital, Chinese Academy of Medical Science
COMPLETEDTianjin, Tianjin Municipality, 300000, China
-
Bon Secours St. Francis Cancer Center
RECRUITINGGreenville, South Carolina, 29607, United States
Contact
-
Cancer prevention and treatment center of Sun Yat sen University
COMPLETEDGuangzhou, Guangdong, China
-
Clinical Research Alliance, Inc.
TERMINATEDLake Success, New York, 11042, United States
-
Guangdong Provincial People's Hospital
COMPLETEDGuangzhou, Guangdong, China
-
Henan Cancer Hospital
COMPLETEDZhengzhou, Henan, 450000, China
-
Linyi Cancer Hospital
COMPLETEDLinyi, Shandong, China
-
MD Anderson
RECRUITINGHouston, Texas, 77091, United States
Contact
-
New York - Presbyterian Hospital
TERMINATEDNew York, New York, 10032, United States
-
O'Neal Comprehensive Cancer Center, University of Alabama
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
-
Ochsner Clinic Foundation
TERMINATEDNew Orleans, Louisiana, 70121, United States
-
Shengjing Hospital Affiliated to China Medical University
COMPLETEDShenyang, Liaoning, China
-
The First Affiliated Hospital Of Nanchang University
COMPLETEDNanchang, Jiangxi, China
-
The First Affiliated Hospital of Bengbu Medical College
COMPLETEDBengbu, Anhui, China
-
The First Affiliated Hospital of Soochow University
COMPLETEDSuzhou, Jiangsu, China
-
The Second Affiliated hospital of Zhejiang University School of Medicine
COMPLETEDHangzhou, Zhejiang, 310000, China
-
UNC School of Medicine, Division of Hematology
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Conditions
Explore the condition pages connected to this study.